OncLive TV

Tracy T. Batchelor, MD, MPH, discusses the rationale for investigating tirabrutinib for the treatment of patients with primary central nervous system lymphoma.

Matthew Galsky, MD, discusses final results from the phase 3 IMvigor130 trial in patients with metastatic urothelial cancer.

Neeraj Agarwal, MD, discusses the role of PARP inhibitors in metastatic castration-resistant prostate cancer and the potential evolutions of the metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer treatment paradigms.

Lindsay Kilburn, MD, discusses key efficacy findings from the phase 2 FIREFLY-1 trial of the investigational type II RAF inhibitor tovorafenib (DAY101) in heavily pretreated pediatric patients with low-grade glioma.

Harry P Erba, MD, PhD, discusses the safety profile and preliminary activity of the investigational menin inhibitor ziftomenib in acute myeloid leukemia.

Heather R. Williams, MD, discusses findings from the phase 3 PRIMA trial in patients with ovarian cancer.

Edgardo Santos, MD, FACP, FCCP, clinical affiliate associate professor, Florida Atlantic University; treasurer, Florida Society of Clinical Oncology, discusses first-line treatment options for patients with ALK-positive non–small cell lung cancer.

Yuan Yuan, MD, PhD, discusses ongoing investigations at Cedars-Sinai of treatment de-escalation in patients with early-stage triple-negative breast cancer according to their pathological response.

George Simon, MD, FACP, FCCP, discusses findings from an FDA pooled analysis of PD-1/PD-L1 inhibitors with or without chemotherapy in patients with non–small cell lung cancer.

Neeraj Agarwal, MD, discusses the significance of the FDA approval of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.

Paola Gehrig, MD, discusses the optimal use and timing of genetic testing in endometrial cancer.

Shakeela Bahadur, MD, discusses how recent data have informed the selection of approved CDK4/6 inhibitors in the frontline setting for patients with metastatic hormone receptor–positive, HER2-negative breast cancer.

Nuhad K. Ibrahim, MD, discusses the investigation of eftilagimod alpha plus in hormone receptor–positive HER2-negative or HER2-low metastatic breast cancer in the phase 3 AIPAC-003 trial.

Andrew S. Brohl, MD, discusses the safety and immunologic responses with intratumoral administration of Idx-Hu2.0 in patients with advanced Merkel cell carcinoma and cutaneous squamous cell carcinoma.

Deb Schrag, MD, MPH, discusses findings from the phase 2/3 PROSPECT trial in patients with rectal cancer.

Danielle K. DePalo, MD, discusses findings from a study comparing first-line isolated limb infusion/perfusion vs immune checkpoint inhibitors and intratumoral therapy in patients with surgically unresectable melanoma in-transit metastases.

Alessandro Santin, MD, discusses the clinical activity of sacituzumab govitecan-hziy in patients with recurrent endometrial cancer who overexpress Trop-2.

Andreas Saltos, MD, discusses final results from a phase 2 trial of first-line pembrolizumab plus vorinostat in patients with metastatic non–small cell lung cancer.

Lova L. Sun, MD, MSCE, discusses the association between duration of immunotherapy and overall survival in patients with advanced non–small-cell lung cancer.

Alexander I. Spira, MD, PhD, FACP, discusses the ongoing phase 3 PACIFIC-8 trial of durvalumab in combination with domvanalimab following concurrent chemoradiotherapy in patients with unresectable stage III non–small cell lung cancer.

Joshua P. Sasine, MD, PhD, discusses the potential role of cilta-cel in earlier lines of therapy for patients with multiple myeloma.

David R. Oveisi, MD, discusses the evolution and potential role of bispecific antibodies in multiple myeloma, and presents several areas of unmet need regarding their use in this space.

Susan M. O’Brien, MD, discusses the use of pirtobrutinib for patients with hematologic malignancies who developed resistance to BTK inhibition.

Carolina D. Schinke, MD, discusses updated findings from the phase 1/2 MonumenTAL-1 trial in patients with multiple myeloma.

Ulka Nitin Vaishampayan, MBBS, discusses findings from the phase 3 CONTACT-03 trial in patients with renal cell carcinoma.

Bradley Monk, MD, FACS, FACOG, discusses findings from the phase 2 RAMP 201 trial in patients with low-grade serous ovarian cancer and the importance of these results within the context of the larger ovarian cancer treatment paradigm. 

James Chih-Hsin Yang, MD, discusses the investigation of pembrolizumab plus pemetrexed and platinum-based chemotherapy in patients with TKI-resistant, EGFR-mutant, metastatic nonsquamous non–small cell lung cancer.

Guru P. Sonpavde, MD, discusses the potential impact of the phase 3 THOR study evaluating erdafitinib vs chemotherapy in patients with advanced or metastatic urothelial cancer harboring FGFR2/3 alterations.

Bruna Pellini, MD, discusses the use of circulating tumor DNA monitoring to inform maintenance outcomes in patients with advanced non–small cell lung cancer treated with induction therapy with atezolizumab, carboplatin, and nab-paclitaxel.

Marilyn Huang, MD, discusses the need for non-chemotherapy options in advanced ovarian cancer, as well as data on the use of neoadjuvant PARP inhibitors for this population in the phase 1 NOW study.